Discontinued — last reported Q4 '23
Covance Drug Development — Amortization
Labcorp Holdings Covance Drug Development — Amortization remained flat by 0.0% to $7.70 in Q4 2023 compared to the prior quarter. Year-over-year, this metric declined by 65.2%, from $22.10 to $7.70. Over 2 years (FY 2021 to FY 2023), Covance Drug Development — Amortization shows a downward trend with a -99.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
High amortization levels are typical following large acquisitions of companies with significant intellectual property.
Detailed definition
The systematic allocation of the cost of intangible assets, such as customer relationships or proprietary technology, ov...
Peer comparison
Standard metric for evaluating the cost of past acquisitions across the CRO industry.
lh_segment_covance_drug_development_amortizationHistorical Data
| FY'21 | FY'22 | FY'23 | |
|---|---|---|---|
| Value | $27.50M | $88.40 | $30.80 |
| YoY Change | — | -100.0% | -65.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's covance drug development — amortization?
- Labcorp Holdings (LH) reported covance drug development — amortization of $7.70 in Q4 2023.
- How has Labcorp Holdings's covance drug development — amortization changed year-over-year?
- Labcorp Holdings's covance drug development — amortization decreased by 65.2% year-over-year, from $22.10 to $7.70.
- What is the long-term trend for Labcorp Holdings's covance drug development — amortization?
- Over 2 years (2021 to 2023), Labcorp Holdings's covance drug development — amortization has grown at a -99.9% compound annual growth rate (CAGR), from $27.50M to $30.80.
- What does covance drug development — amortization mean?
- The annual expense of spreading the cost of intangible assets over time.